VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company’s capital strategy, strategic opportunities, and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
The appointment comes at a critical time for VERAXA as it advances its pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative antibody formats. With Willener’s extensive background in financial strategy and capital markets, the company aims to strengthen its position in the competitive oncology space. His experience includes serving as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing areas including corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
Willener’s appointment is likely to enhance VERAXA’s ability to secure funding and forge strategic partnerships, which are essential for advancing its clinical programs. The company’s proprietary BiTAC technology platform, based on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), represents a promising approach to cancer therapy. By integrating Willener’s financial expertise, VERAXA is better positioned to navigate the complex landscape of biotech financing and bring its therapies to patients in need.
This leadership change underscores VERAXA’s commitment to robust financial management as it seeks to capitalize on its innovative pipeline. Investors and industry observers will be watching closely to see how Willener’s strategic guidance influences the company’s trajectory. The full press release can be viewed at https://nnw.fm/jcHOU.
For more information about VERAXA Biotech and its latest updates, visit the company’s newsroom at http://nnw.fm/VRXA.
